Citius Net Receivables vs Deferred Long Term Liab Analysis

CTXR Stock

USD 0.66 0.07 9.59%

Citius Pharmaceuticals financial indicator trend analysis is way more than just evaluating Citius Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Citius Pharmaceuticals is a good investment. Please check the relationship between Citius Pharmaceuticals Net Receivables and its Deferred Long Term Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Citius Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.

To learn how to invest in Citius Stock, please use our How to Invest in Citius Pharmaceuticals guide.

Net Receivables vs Deferred Long Term Liab

Net Receivables vs Deferred Long Term Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Citius Pharmaceuticals Net Receivables account and Deferred Long Term Liab. At this time, the significance of the direction appears to have strong relationship.

The correlation between Citius Pharmaceuticals' Net Receivables and Deferred Long Term Liab is 0.73. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Deferred Long Term Liab in the same time period over historical financial statements of Citius Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Citius Pharmaceuticals' Net Receivables and Deferred Long Term Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of Citius Pharmaceuticals are associated (or correlated) with its Deferred Long Term Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Deferred Long Term Liab has no effect on the direction of Net Receivables i.e., Citius Pharmaceuticals' Net Receivables and Deferred Long Term Liab go up and down completely randomly.

Correlation Coefficient

0.73

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Net Receivables

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.

Most indicators from Citius Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Citius Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Citius Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.

To learn how to invest in Citius Stock, please use our How to Invest in Citius Pharmaceuticals guide.At this time, Citius Pharmaceuticals' Selling General Administrative is relatively stable compared to the past year. As of 04/27/2024, Tax Provision is likely to grow to about 695.5 K, while Enterprise Value Multiple is likely to drop (2.01).

Citius Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Net Tangible Assets	Retained Earnings Total Equity	Capital Surpluse	Other Stockholder Equity	Other Liab	Current Deferred Revenue	Non Current Assets Total	Other Assets	Long Term Debt
Total Assets		0.41	0.66	0.77	1.0	-0.88	-0.93	0.71	0.87	0.87	0.94	0.94	0.89	0.91	0.96	-0.13	0.94	0.98	-0.94	0.98	0.97	0.62	0.51	0.98	0.33	0.63
Short Long Term Debt Total	0.41		0.58	0.48	0.39	-0.44	-0.38	0.27	0.45	0.45	0.44	0.32	0.52	0.56	0.42	0.55	0.42	0.4	-0.43	0.39	0.37	0.5	0.5	0.39	0.65	0.49
Other Current Liab	0.66	0.58		0.84	0.65	-0.53	-0.65	0.54	0.55	0.55	0.68	0.58	0.65	0.72	0.56	0.38	0.66	0.56	-0.68	0.65	0.63	0.76	0.73	0.7	0.59	0.72
Total Current Liabilities	0.77	0.48	0.84		0.75	-0.49	-0.84	0.89	0.48	0.48	0.8	0.77	0.87	0.9	0.62	0.24	0.8	0.69	-0.82	0.83	0.83	0.78	0.68	0.84	0.59	0.8
Total Stockholder Equity	1.0	0.39	0.65	0.75		-0.9	-0.91	0.68	0.88	0.88	0.94	0.93	0.87	0.89	0.97	-0.14	0.93	0.98	-0.93	0.97	0.96	0.61	0.5	0.98	0.32	0.62
Net Debt	-0.88	-0.44	-0.53	-0.49	-0.9		0.7	-0.39	-0.99	-0.99	-0.75	-0.71	-0.69	-0.67	-0.97	0.18	-0.72	-0.86	0.76	-0.79	-0.76	-0.47	-0.43	-0.78	-0.25	-0.45
Retained Earnings	-0.93	-0.38	-0.65	-0.84	-0.91	0.7		-0.84	-0.7	-0.7	-0.91	-0.96	-0.94	-0.95	-0.82	0.1	-0.92	-0.91	0.99	-0.97	-0.98	-0.67	-0.55	-0.96	-0.39	-0.66
Accounts Payable	0.71	0.27	0.54	0.89	0.68	-0.39	-0.84		0.38	0.38	0.7	0.76	0.88	0.85	0.55	0.0	0.72	0.66	-0.8	0.8	0.82	0.7	0.58	0.79	0.5	0.73
Cash	0.87	0.45	0.55	0.48	0.88	-0.99	-0.7	0.38		1.0	0.74	0.7	0.68	0.66	0.96	-0.18	0.71	0.85	-0.76	0.78	0.75	0.48	0.45	0.77	0.25	0.44
Cash And Short Term Investments	0.87	0.45	0.55	0.48	0.88	-0.99	-0.7	0.38	1.0		0.74	0.7	0.68	0.66	0.96	-0.18	0.71	0.85	-0.76	0.78	0.75	0.48	0.45	0.77	0.25	0.44
Common Stock Total Equity	0.94	0.44	0.68	0.8	0.94	-0.75	-0.91	0.7	0.74	0.74		0.96	0.86	0.93	0.87	0.05	1.0	0.96	-0.89	0.95	0.95	0.55	0.42	0.95	0.43	0.56
Common Stock Shares Outstanding	0.94	0.32	0.58	0.77	0.93	-0.71	-0.96	0.76	0.7	0.7	0.96		0.89	0.93	0.85	-0.11	0.97	0.96	-0.94	0.98	0.98	0.54	0.39	0.97	0.31	0.55
Non Current Liabilities Total	0.89	0.52	0.65	0.87	0.87	-0.69	-0.94	0.88	0.68	0.68	0.86	0.89		0.96	0.79	-0.05	0.86	0.86	-0.95	0.93	0.93	0.68	0.57	0.92	0.53	0.7
Total Liab	0.91	0.56	0.72	0.9	0.89	-0.67	-0.95	0.85	0.66	0.66	0.93	0.93	0.96		0.8	0.06	0.93	0.89	-0.94	0.95	0.95	0.68	0.56	0.95	0.5	0.7
Total Current Assets	0.96	0.42	0.56	0.62	0.97	-0.97	-0.82	0.55	0.96	0.96	0.87	0.85	0.79	0.8		-0.16	0.86	0.95	-0.85	0.9	0.88	0.51	0.43	0.9	0.27	0.51
Short Term Debt	-0.13	0.55	0.38	0.24	-0.14	0.18	0.1	0.0	-0.18	-0.18	0.05	-0.11	-0.05	0.06	-0.16		0.04	-0.14	0.12	-0.11	-0.11	0.27	0.28	-0.1	0.57	0.29
Common Stock	0.94	0.42	0.66	0.8	0.93	-0.72	-0.92	0.72	0.71	0.71	1.0	0.97	0.86	0.93	0.86	0.04		0.95	-0.89	0.95	0.96	0.55	0.41	0.95	0.42	0.56
Net Tangible Assets	0.98	0.4	0.56	0.69	0.98	-0.86	-0.91	0.66	0.85	0.85	0.96	0.96	0.86	0.89	0.95	-0.14	0.95		-0.91	0.97	0.96	0.51	0.39	0.96	0.28	0.52
Retained Earnings Total Equity	-0.94	-0.43	-0.68	-0.82	-0.93	0.76	0.99	-0.8	-0.76	-0.76	-0.89	-0.94	-0.95	-0.94	-0.85	0.12	-0.89	-0.91		-0.97	-0.96	-0.71	-0.6	-0.96	-0.41	-0.69
Capital Surpluse	0.98	0.39	0.65	0.83	0.97	-0.79	-0.97	0.8	0.78	0.78	0.95	0.98	0.93	0.95	0.9	-0.11	0.95	0.97	-0.97		1.0	0.64	0.52	0.99	0.36	0.66
Other Stockholder Equity	0.97	0.37	0.63	0.83	0.96	-0.76	-0.98	0.82	0.75	0.75	0.95	0.98	0.93	0.95	0.88	-0.11	0.96	0.96	-0.96	1.0		0.64	0.5	0.99	0.35	0.65
Other Liab	0.62	0.5	0.76	0.78	0.61	-0.47	-0.67	0.7	0.48	0.48	0.55	0.54	0.68	0.68	0.51	0.27	0.55	0.51	-0.71	0.64	0.64		0.98	0.67	0.7	0.98
Current Deferred Revenue	0.51	0.5	0.73	0.68	0.5	-0.43	-0.55	0.58	0.45	0.45	0.42	0.39	0.57	0.56	0.43	0.28	0.41	0.39	-0.6	0.52	0.5	0.98		0.54	0.69	0.94
Non Current Assets Total	0.98	0.39	0.7	0.84	0.98	-0.78	-0.96	0.79	0.77	0.77	0.95	0.97	0.92	0.95	0.9	-0.1	0.95	0.96	-0.96	0.99	0.99	0.67	0.54		0.36	0.68
Other Assets	0.33	0.65	0.59	0.59	0.32	-0.25	-0.39	0.5	0.25	0.25	0.43	0.31	0.53	0.5	0.27	0.57	0.42	0.28	-0.41	0.36	0.35	0.7	0.69	0.36		0.69
Long Term Debt	0.63	0.49	0.72	0.8	0.62	-0.45	-0.66	0.73	0.44	0.44	0.56	0.55	0.7	0.7	0.51	0.29	0.56	0.52	-0.69	0.66	0.65	0.98	0.94	0.68	0.69

Click cells to compare fundamentals

Citius Pharmaceuticals Account Relationship Matchups

Citius Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	43.8M	142.4M	114.0M	103.6M	119.2M	125.1M
Short Long Term Debt Total	1.4M	855.5K	678.2K	481.2K	553.4K	476.4K
Other Current Liab	1.9M	2.5M	3.2M	2.6M	3.0M	1.8M
Total Current Liabilities	4.1M	4.0M	4.5M	5.8M	6.6M	7.0M
Total Stockholder Equity	33.7M	132.2M	102.8M	90.8M	104.5M	109.7M
Net Debt	(12.5M)	(69.2M)	(41.0M)	(26.0M)	(23.4M)	(22.2M)
Retained Earnings	(70.6M)	(96.0M)	(129.7M)	(162.2M)	(146.0M)	(138.7M)
Accounts Payable	1.9M	1.3M	1.2M	2.9M	3.4M	3.5M
Cash	13.9M	70.1M	41.7M	26.5M	30.5M	16.0M
Cash And Short Term Investments	13.9M	70.1M	41.7M	26.5M	30.5M	16.0M
Common Stock Total Equity	28.9K	55.6K	146.0K	146.2K	168.1K	176.6K
Common Stock Shares Outstanding	39.2M	108.6M	146.1M	151.3M	174.0M	182.7M
Liabilities And Stockholders Equity	43.8M	142.4M	114.0M	103.6M	119.2M	125.1M
Non Current Liabilities Total	6.0M	5.7M	6.0M	6.4M	7.4M	7.7M
Total Liab	10.1M	9.6M	10.6M	12.2M	14.0M	14.7M
Total Current Assets	14.0M	72.8M	44.6M	34.4M	39.5M	41.5M
Short Term Debt	332.0K	177.2K	197.0K	218.4K	251.1K	295.7K
Common Stock	55.6K	146.0K	146.2K	158.9K	182.7K	191.8K
Net Tangible Assets	(1.6M)	33.7M	132.2M	102.8M	118.2M	124.2M
Retained Earnings Total Equity	(55.8M)	(70.6M)	(96.0M)	(129.7M)	(116.7M)	(110.9M)
Capital Surpluse	80.2M	104.2M	228.1M	232.4M	267.2M	280.6M
Other Stockholder Equity	104.2M	228.1M	232.4M	252.9M	290.8M	305.4M
Non Current Assets Total	29.8M	69.6M	69.4M	69.2M	79.6M	83.6M
Other Current Assets	122.2K	2.7M	2.9M	7.9M	9.1M	9.5M
Property Plant Equipment	590.0	1.6K	7.0K	4.1K	4.7K	3.0K
Property Plant And Equipment Net	987.8K	829.9K	650.2K	455.9K	524.2K	403.2K
Property Plant And Equipment Gross	987.8K	829.9K	650.2K	455.9K	524.2K	403.2K
Net Invested Capital	34.0M	132.2M	102.8M	90.8M	104.5M	68.3M
Net Working Capital	9.9M	68.8M	40.0M	28.6M	32.9M	24.9M
Capital Stock	55.6K	146.0K	146.2K	158.9K	182.7K	101.2K

Pair Trading with Citius Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Citius Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Citius Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Citius Stock

0.66	ELEV	Elevation Oncology Earnings Call This Week	Pair Corr
0.7	FHTX	Foghorn TherapeuticsInc Financial Report 13th of May 2024	Pair Corr

Moving against Citius Stock

0.5	MOLN	Molecular Partners Financial Report 10th of May 2024	Pair Corr
0.44	BNTX	BioNTech SE Financial Report 13th of May 2024	Pair Corr

The ability to find closely correlated positions to Citius Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Citius Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Citius Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Citius Pharmaceuticals to buy it.

The correlation of Citius Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Citius Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Citius Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Citius Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Citius Pharmaceuticals is a strong investment it is important to analyze Citius Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Citius Pharmaceuticals' future performance. For an informed investment choice regarding Citius Stock, refer to the following important reports:

How To Invest In Citius

Details

Is Citius Stock a good investment?

Details

What is Citius Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Citius Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.

To learn how to invest in Citius Stock, please use our How to Invest in Citius Pharmaceuticals guide.

You can also try the Stocks Directory module to find actively traded stocks across global markets.

Complementary Tools for Citius Stock analysis

When running Citius Pharmaceuticals' price analysis, check to measure Citius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Pharmaceuticals is operating at the current time. Most of Citius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Citius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Citius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Money Managers Screen money managers from public funds and ETFs managed around the world
	Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
	Content Syndication Quickly integrate customizable finance content to your own investment portal
	Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges
	Global Correlations Find global opportunities by holding instruments from different markets
	Commodity Directory Find actively traded commodities issued by global exchanges
	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges
	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity

Is Citius Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Citius Pharmaceuticals. If investors know Citius will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Citius Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.26)

Return On Assets

(0.23)

Return On Equity

(0.41)

The market value of Citius Pharmaceuticals is measured differently than its book value, which is the value of Citius that is recorded on the company's balance sheet. Investors also form their own opinion of Citius Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Citius Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Citius Pharmaceuticals' market value can be influenced by many factors that don't directly affect Citius Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Citius Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Citius Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Citius Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Citius Net Receivables vs Deferred Long Term Liab Analysis

Net Receivables vs Deferred Long Term Liab

Net Receivables vs Deferred Long Term Liab Correlation Analysis

Correlation Coefficient

Net Receivables

Deferred Long Term Liab

Citius Pharmaceuticals fundamental ratios Correlations

Citius Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Citius Pharmaceuticals fundamental ratios Accounts

Pair Trading with Citius Pharmaceuticals

Moving together with Citius Stock

Moving against Citius Stock

Complementary Tools for Citius Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Common Stock	+ 1.0	Common Stock Total Equity
Other Stockholder Equity	+ 1.0	Capital Surpluse
Retained Earnings Total Equity	+ 0.99	Retained Earnings
Non Current Assets Total	+ 0.99	Capital Surpluse

Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Other Stockholder Equity	- 0.98	Retained Earnings
Capital Surpluse	- 0.97	Retained Earnings Total Equity
Capital Surpluse	- 0.97	Retained Earnings
Total Current Assets	- 0.97	Net Debt